Despite a robust HIV portfolio and growing oncology sales, Gilead struggles to diversify revenue streams significantly. Learn ...

This analysis delves into the latest insights on Gilead Sciences. The consensus rating ... with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset ...

Gilead Sciences ( GILD) increased its growth forecast for the year on strong third quarter results, marking a shift away from ...

The aggregate market capitalisation of the 20 largest drugmakers grew by 2% overall to reach $4.3tn. Among these, Bristol ...

J.P. Morgan analyst Chris Schott maintained a Buy rating on Gilead Sciences (GILD – Research Report) yesterday and set a price target of ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

Following the remarkable 100% efficacy reported from an interim analysis ... have in our portfolio and the combinations that ...

November 06, 2024--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq ... The Liver Disease portfolio sales increased 4% to $733 million in the third quarter 2024 compared to the same period in ...

Operator Good afternoon, everyone, and welcome to Gilead's third quarter 2024 earnings conference call. My name is Rebecca, and I'll be your host for today. In a moment, we'll begin with our prepared ...

Gilead (GILD) announced the upcoming presentation of HIV research findings at the International Congress on Drug Therapy in HIV Infection, ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the upcoming presentation of HIV research findings at the International ...

The consensus rating for Gilead Sciences is Neutral, based on 16 analyst ratings. With an average one-year price target of $84.25, there's a potential 6.22% downside.